This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kumar-Sinha, C. Articles by Chinnaiyan, A. M. Search for Related Content PubMed PubMed Citation Articles by Kumar-Sinha, C. Articles by Chinnaiyan, A. M.

(American Journal of Pathology. 2004;164:787-793.)
© 2004 American Society for Investigative Pathology

Short Communication

Elevated -Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer

Chandan Kumar-Sinha^*, Rajal B. Shah^*, Bharathi Laxman^*, Scott A. Tomlins^*, Jason Harwood^*, Werner Schmitz, Ernst Conzelmann, Martin G. Sanda, John T. Wei, Mark A. Rubin and Arul M. Chinnaiyan^*¶||

From the Departments of Pathology^*and Urology,Michigan Urology Center,^¶and the Comprehensive Cancer Center,||University of Michigan Medical School, Ann Arbor, Michigan; the Department of Pathology,Brigham and Woman’s Hospital, Harvard Medical School, Boston, Massachusetts; and the Theodor-Boveri-Institut fur Biowissenschaften (Biozentrum) der Universitat Wurzburg,Wurzburg, Germany

-Methylacyl-CoA racemase (AMACR) is a peroxisomal and mitochondrial enzyme involved in the ß-oxidation of branched fatty acids, shown to be elevated in prostate cancer by several recent studies. Sequence variants of AMACR have been linked to prostate cancer risk. Although mRNA transcript, protein, and sequence variants of AMACR have been studied in the context of prostate cancer, AMACR enzymatic activity has not been addressed. Here we present evidence that AMACR activity is consistently elevated in prostate cancer tissue specimens. This activity can be immunodepleted from prostate cancer tissue extracts. Furthermore, mock needle biopsy cores containing foci of prostate cancer exhibited increased AMACR enzymatic activity, correlating with both protein levels and histopathology. Taken together, our studies suggest that AMACR activity is increased in prostate cancer relative to benign epithelia and suggests that monitoring AMACR activity levels in prostate needle biopsies may have clinical applications.

This article has been cited by other articles:

				B. Laxman, D. S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra, R. J. Lonigro, A. Tsodikov, J. T. Wei, S. A. Tomlins, et al. A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer Cancer Res., February 1, 2008; 68(3): 645 - 649. [Abstract] [Full Text] [PDF]

				J. Masumoto, K. Yang, S. Varambally, M. Hasegawa, S. A. Tomlins, S. Qiu, Y. Fujimoto, A. Kawasaki, S. J. Foster, Y. Horie, et al. Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo J. Exp. Med., January 23, 2006; 203(1): 203 - 213. [Abstract] [Full Text] [PDF]

				M. A. Rubin, T. A. Bismar, O. Andren, L. Mucci, R. Kim, R. Shen, D. Ghosh, J. T. Wei, A. M. Chinnaiyan, H.-O. Adami, et al. Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1424 - 1432. [Abstract] [Full Text] [PDF]

				K. Savolainen, P. Bhaumik, W. Schmitz, T. J. Kotti, E. Conzelmann, R. K. Wierenga, and J. K. Hiltunen {alpha}-Methylacyl-CoA Racemase from Mycobacterium tuberculosis: MUTATIONAL AND STRUCTURAL CHARACTERIZATION OF THE ACTIVE SITE AND THE FOLD J. Biol. Chem., April 1, 2005; 280(13): 12611 - 12620. [Abstract] [Full Text] [PDF]